SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001725160-24-000122
Filing Date
2024-05-29
Accepted
2024-05-29 07:33:01
Documents
3
Period of Report
2024-05-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1716982327.html 3  
1 FORM 3 wk-form3_1716982327.xml 3 1664
2 EX-24 pagesfromlwalkerpoa.htm EX-24 3827
3 GRAPHIC pagesfromlwalkerpoa001.jpg GRAPHIC 233623
  Complete submission text file 0001725160-24-000122.txt   329016
Mailing Address C/O CASCADIAN THERAPEUTICS, INC. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
Walker Luke Nathaniel (Reporting) CIK: 0001701440 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 24994024

Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)